DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer

Information source: Asan Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Advanced Gastric Cancer

Intervention: RAD001, Capecitabine, Oxaliplatin (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Asan Medical Center

Official(s) and/or principal investigator(s):
Yoon-Koo Kang, MD, PhD, Principal Investigator, Affiliation: Asan Medical Center


It is expected that RAD001 works in gastric cancer by inhibiting PI3K/AKT/mTOR pathway and Hif1A (hypoxia inducible factor 1, alpha subunit), a key player in angiogenesis and the growth of tumors like renal cell carcinoma. However, RAD001 alone looks not enough to control gastric cancer. By the mechanisms above, RAD001 can show additive or synergistic effect in combination with conventional chemotherapy. In this study, XELOX was selected as a conventional combination chemotherapy because it was proven very active and safe in gastric cancer. Combination of XELOX and RAD001 has been never tried for the treatment of cancer patients yet. So, the optimal dose will be first determined in this phase I study

Clinical Details

Official title: A Phase I Dose Finding Study of RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer

Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To assess the maximum tolerated dose (MTD)

Secondary outcome:

Progression-free survival

Overall survival

Biomarker study

Response rate

Detailed description: For the first cohort of this phase I study, each drug of capecitabine, oxaliplatin, and RAD001 will be started at one or two dose below the ordinary full dose of each drug as a single agent.


Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.


Inclusion Criteria:

- Histologically or cytologically documented unresectable or metastatic adenocarcinoma

of stomach or gastroesophageal junction

- No history of chemotherapy or radiation

- Age 18 to 70 years old

- Estimated life expectancy of at least 3 months

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Adequate bone marrow function (white blood cell counts >3,000/uL, absolute neutrophil

count>1,500/uL, Platelets>100,000/uL, Hgb>8 g/dL)

- Adequate kidney function (creatinine<1. 5 mg/dL)

- Adequate liver function (bilirubin<1. 5 mg/dL, aspartate aminotransferase (AST) or

alanine aminotransferase (ALT) level <3 times the upper normal limit (5 times for patients with liver metastasis))

- Signed written informed consent

Exclusion Criteria:

- Past or concurrent history of neoplasm other than gastric adenocarcinoma except for

curatively treated basal cell carcinoma of skin or in situ carcinoma of the cervix uteri

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days

prior to study treatment start

- Presence of central nervous system metastasis

- Bowel obstruction

- Evidence of serious gastrointestinal bleeding

- Peripheral neuropathy (NCI CTC AE version 3. 0 > Grade I)

- History of significant neurologic or psychiatric disorders

- Pregnant or lactating women, women of childbearing potential not employing adequate


- Other serious illness or medical conditions

- Patients with known history of ischemic heart disease and/or with myocardial


- Known allergy to study drugs

- Administration of drugs showing interaction with RAD001

Locations and Contacts

Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Korea, Republic of
Additional Information

Starting date: February 2010
Last updated: January 11, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017